Cited by

• Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

  Greenberg AJ, Vachon CM, Rajkumar SV. Greenberg AJ, et al. Leukemia. 2012 Apr;26(4):609-14. doi: 10.1038/leu.2011.368. Epub 2011 Dec 23. Leukemia. 2012. PMID: 22193966 Free PMC article. Review.
• Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.

  Ailawadhi S, Swaika A, Razavi P, Yang D, Chanan-Khan A. Ailawadhi S, et al. Blood Cancer J. 2014 Sep 5;4(9):e243. doi: 10.1038/bcj.2014.63. Blood Cancer J. 2014. PMID: 25192415 Free PMC article.
• Prevalence of monoclonal gammopathy of undetermined significance in Thailand.

  Watanaboonyongcharoen P, Nakorn TN, Rojnuckarin P, Lawasut P, Intragumtornchai T. Watanaboonyongcharoen P, et al. Int J Hematol. 2012 Feb;95(2):176-81. doi: 10.1007/s12185-011-0995-4. Epub 2012 Jan 12. Int J Hematol. 2012. PMID: 22234527
• Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.

  Steiner N, Göbel G, Suchecki P, Prokop W, Neuwirt H, Gunsilius E. Steiner N, et al. Oncotarget. 2017 Dec 18;9(2):2344-2356. doi: 10.18632/oncotarget.23412. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416776 Free PMC article.
• With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.

  Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC. Fillmore NR, et al. Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19. Blood. 2019. PMID: 31003998 Free PMC article. No abstract available.